RESUMEN
BACKGROUND AND OBJECTIVE: Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. METHODS: Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission and no response), and subjective impairment by a 3-point scale (severe, moderate and none). RESULTS: Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months respectively; 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. CONCLUSION: Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.
Asunto(s)
Carcinoma de Células Escamosas , Liquen Plano Oral , Humanos , Femenino , Anciano , Masculino , Tacrolimus , Liquen Plano Oral/tratamiento farmacológico , Liquen Plano Oral/patología , Estudios Retrospectivos , Inmunosupresores/uso terapéutico , Administración Tópica , Resultado del Tratamiento , Recurrencia Local de Neoplasia/tratamiento farmacológico , Carcinoma de Células Escamosas/tratamiento farmacológico , Protocolos ClínicosAsunto(s)
COVID-19 , Psoriasis , Vacunas contra la COVID-19 , Humanos , SARS-CoV-2 , Vacunación/efectos adversosAsunto(s)
Dermatitis , Trastornos Leucocíticos , Síndrome de Sweet , Humanos , Neutrófilos , Síndrome de Sweet/etiologíaRESUMEN
LL37 exerts a dual pathogenic role in psoriasis. Bound to self-DNA/RNA, LL37 licenses autoreactivity by stimulating plasmacytoid dendritic cells-(pDCs)-Type I interferon (IFN-I) and acts as autoantigen for pathogenic Th17-cells. In systemic lupus erythematosus (SLE), LL37 also triggers IFN-I in pDCs and is target of pathogenic autoantibodies. However, whether LL37 activates T-cells in SLE and how the latter differ from psoriasis LL37-specific T-cells is unknown. Here we found that 45% SLE patients had circulating T-cells strongly responding to LL37, which correlate with anti-LL37 antibodies/disease activity. In contrast to psoriatic Th17-cells, these LL37-specific SLE T-cells displayed a T-follicular helper-(TFH)-like phenotype, with CXCR5/Bcl-6 and IL-21 expression, implicating a role in stimulation of pathogenic autoantibodies. Accordingly, SLE LL37-specific T-cells promoted B-cell secretion of pathogenic anti-LL37 antibodies in vitro. Importantly, we identified abundant citrullinated LL37 (cit-LL37) in SLE tissues (skin and kidney) and observed very pronounced reactivity of LL37-specific SLE T-cells to cit-LL37, compared to native-LL37, which was much more occasional in psoriasis. Thus, in SLE, we identified LL37-specific T-cells with a distinct functional specialization and antigenic specificity. This suggests that autoantigenic specificity is independent from the nature of the autoantigen, but rather relies on the disease-specific milieu driving T-cell subset polarization and autoantigen modifications.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/inmunología , Autoanticuerpos/inmunología , Lupus Eritematoso Sistémico/inmunología , Linfocitos T/inmunología , Anticuerpos Antiproteína Citrulinada/inmunología , Anticuerpos Antinucleares/inmunología , Formación de Anticuerpos/inmunología , ADN/inmunología , Células Dendríticas/inmunología , Femenino , Humanos , Lupus Eritematoso Sistémico/etiología , Masculino , Psoriasis/etiología , Psoriasis/inmunología , Células Th17/inmunología , CatelicidinasRESUMEN
Autoinflammation leads to inflammation that mostly occurs without any clinically obvious reason. It can be so severe that organ damage with relevant tissue damage occurs. Inflammasomes are the drivers of autoinflammation. Although IL1 beta and the inflammasomes as its critical regulators are very important in autoinflammation, not all patients respond to inhibition of this signalling pathway. Several autoinflammatory diseases were associated with mutations in proteasome-immunoproteasome components. Autoinflammatory diseases caused by highly relevant genetic variants are mostly hereditary. Usually in childhood but not always. The coming years will show whether inflammatory dermatoses will be increasingly treated with suppression of the innate immune system in addition to inhibition of adaptive immunity.
Asunto(s)
Dermatitis/fisiopatología , Enfermedades Autoinflamatorias Hereditarias/fisiopatología , Enfermedades de la Piel/fisiopatología , Niño , Humanos , Inmunidad Innata , Inflamasomas , InflamaciónAsunto(s)
Erupciones Liquenoides , Penfigoide Benigno de la Membrana Mucosa , Penfigoide Ampolloso , Humanos , Inhibidores de Puntos de Control Inmunológico , Membrana Mucosa , Penfigoide Benigno de la Membrana Mucosa/inducido químicamente , Penfigoide Benigno de la Membrana Mucosa/tratamiento farmacológico , Penfigoide Ampolloso/inducido químicamenteAsunto(s)
Liquen Plano Oral/diagnóstico , Penfigoide Benigno de la Membrana Mucosa/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Autoanticuerpos/sangre , Diagnóstico Diferencial , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Penfigoide Benigno de la Membrana Mucosa/tratamiento farmacológico , Penfigoide Benigno de la Membrana Mucosa/patología , Estudios Retrospectivos , Esteroides/uso terapéutico , Tacrolimus/uso terapéuticoRESUMEN
Rosacea (in German sometimes called 'Kupferfinne', in French 'Couperose' and in Italian 'Copparosa') is a chronic and frequently relapsing inflammatory skin disease primarily affecting the central areas of the face. Its geographic prevalence varies from 1% to 22%. The differential diagnosis is wide, and the treatment is sometimes difficult and varies by stage of rosacea. For erythematous lesions and telangiectasia, intense pulsed light (IPL) therapy and lasers are popular treatment option. In addition, a vasoconstrictor agent, brimonidine, has recently been developed. For papulopustular rosacea, topical antibiotics, topical and systemic retinoids, as well as systemic antibiotics are used. A topical acaricidal agent, ivermectin, has undergone clinical development and is now on the market. In the later stages, hyperplasia of the sebaceous glands develops, resulting in phymatous growths such as the frequently observed bulbous nose or rhinophyma. Ablative laser treatments have largely replaced classical abrasive tools. Here, we reviewed the current evidence on the treatment of rosacea, provide a guideline (S1 level) and discuss the differential diagnosis of rosacea.
Asunto(s)
Guías de Práctica Clínica como Asunto , Rosácea/terapia , Diagnóstico Diferencial , Humanos , Rosácea/diagnóstico , Rosácea/epidemiología , Rosácea/patología , SuizaRESUMEN
BACKGROUND: Axillary hyperhidrosis is a common and distressing problem interfering with the life of affected individuals. Currently, local surgery is the treatment of choice once conservative treatment has failed. OBJECTIVES: To evaluate the clinical efficacy and safety of tumescent suction curettage (TSC) in treating axillary hyperhidrosis and to correlate it with histological markers. METHODS: Thirty patients (17 females and 13 males, average age 29.9 years) underwent TSC. After tumescent anaesthesia, a suction cannula was inserted in the axilla on each side through two tiny incisions and subcutaneous tissue was removed by suction. We evaluated the clinical efficacy and complications, and in a subset of patients performed biopsies before surgery, as well as 1 month and 1 year after the operation. RESULTS: In comparison with preoperative values, the sweat rate was diminished by 85% after 1 month, 71% after 6 months, 77% after 12 months and 61% after 24 months. The reduced efficacy with time was histologically correlated with an increase in the innervation, whereas the number of sweat glands continued to diminish. The majority of patients were satisfied with the operation but the satisfaction diminished with time. Patients with the highest preoperative sweat rates were the most satisfied after the intervention. CONCLUSION: TSC is an effective and safe treatment for axillary hyperhidrosis. The long-term recurrence may be due to reinnervation.
Asunto(s)
Anestesia/métodos , Legrado , Hiperhidrosis/cirugía , Adolescente , Adulto , Anciano , Axila , Biopsia , Legrado/efectos adversos , Femenino , Humanos , Hiperhidrosis/patología , Hiperhidrosis/fisiopatología , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Piel/inervación , Tejido Subcutáneo/cirugía , Succión , Glándulas Sudoríparas/patología , Sudoración , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Dermocorticoids represent a significant part of the therapeutic arsenal in dermatology due to their anti-inflammatory and anti-proliferative effects, with an indication in numerous inflammatory dermatoses. Their cutaneous side effects are feared but are also often over-estimated. On the other hand, the systemic adverse effects are less well studied. We present here the properties of this medicament class and especially the rules to respect to avoid adverse reactions.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Glucocorticoides/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Administración Tópica , Antiinflamatorios/administración & dosificación , Antiinflamatorios/efectos adversos , Antiinflamatorios/uso terapéutico , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Erupciones por Medicamentos/etiología , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Enfermedades de la Piel/patologíaRESUMEN
Organ transplant recipients (OTR) are at high risk for cutaneous squamous cell carcinomas (SCC). We aimed to define clinically meaningful patient-reported warning signals predicting the presence of invasive SCC.Patient-reported signs and symptoms of 812 consecutively biopsied skin lesions from 410 OTR were determined by questionnaire and physical examination and related to the subsequent biopsy-proven diagnoses. Receiver-operating characteristic (ROC) curve analyses were used as a measure of distinction between the predictive values of patient-reported warning signals and the occurrence of SCC. Pain was an independent predictive patient-reported warning signal for a biopsy-proven invasive SCC. The odds ratio from the fully adjusted model predicting SCC was 4.4(95% confidence interval: 2.48.2). Higher scores on the visual analog scale (VAS) for pain were associated witha greater likelihood for the presence of SCC compared to none or mild pain. The for scores on the VAS from 1to 3, 4 to 6 and 7 to 10 were 4.9 (2.210.5), 2.3 (0.965.5)and 16.5 (3.675.8), respectively. Pain is the most powerful patient-reported warning signal for invasive cutaneous SCC in OTR. Empowerment of patients by education could accelerate diagnosis and treatment of cutaneous SCC.
Asunto(s)
Carcinoma de Células Escamosas/diagnóstico , Trasplante de Órganos/efectos adversos , Dolor/diagnóstico , Neoplasias Cutáneas/diagnóstico , Adulto , Anciano , Carcinoma de Células Escamosas/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Factores de Riesgo , Neoplasias Cutáneas/etiología , Encuestas y CuestionariosRESUMEN
BACKGROUND: Recent studies suggest that patients on mammalian target of rapamycin (mTOR) inhibitors experience a reduction in cutaneous carcinogenesis by an estimated 50% or more compared with calcineurin inhibitors. While randomized trials are running, organ transplant recipients are frequently switched from calcineurin inhibitors to mTOR inhibitors when cutaneous carcinogenesis increases. OBJECTIVES: To slow carcinogenesis in our patient, a heart transplant recipient with a neuropathic diabetic foot syndrome who had developed cutaneous carcinogenesis at a rate of more than 20 squamous cell carcinomas (SCC) annually. METHODS: The patient's immunosuppression was switched from the calcineurin inhibitor ciclosporin to the mTOR inhibitor everolimus. RESULTS: Carcinogenesis slowed to six SCC annually; however, he developed recalcitrant diabetic foot ulcers which were purely neuropathic and nonangiopathic, and a limb-threatening fistulating necrotic erysipelas of the right leg. Both sites responded poorly to antibiotic therapy, offloading and debridement. This skin fistula became chronic and some toes were at risk for minor amputation. In view of the propensity for mTOR inhibitors to impair would healing, immunosuppression was switched back to ciclosporin. All wounds healed rapidly, but skin carcinogenesis rose to former levels. CONCLUSIONS: This case impressively illustrates the clinical dilemma for mTOR inhibitor use where benefit in carcinogenesis is counterbalanced by impairment in wound healing. Changes in immunosuppressive regimens should thus be made on an individual basis with careful consideration of the relative risks.
Asunto(s)
Pie Diabético/fisiopatología , Inmunosupresores/efectos adversos , Neoplasias Cutáneas/prevención & control , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Cicatrización de Heridas/efectos de los fármacos , Anciano , Inhibidores de la Calcineurina , Cardiomiopatía Dilatada/cirugía , Transformación Celular Neoplásica/efectos de los fármacos , Sustitución de Medicamentos , Everolimus , Trasplante de Corazón , Humanos , Masculino , Sirolimus/efectos adversos , Sirolimus/análogos & derivados , Sirolimus/antagonistas & inhibidores , Dedos del PieRESUMEN
Vitamin D, ultraviolets and skin cancer The vitamin D supply is fundamental for the prevention of falls and fractures in aged people, among other effects. UVB triggers vitamin D synthesis in the skin. This relationship has recently gained attention both with the general public and with health care professionals. Some authors suggest a relaxation of UV protection measures, while others even advocate regular sunlight exposure in order to increase cutaneous vitamin D synthesis. However, the UV irradiation responsible for vitamin D synthesis also is a known carcinogen. UV exposure is an insufficient and harmful method to increase vitamin D synthesis. Oral supplementation is the recommended way to prevent and cure vitamin D deficiency.